Jamil Paradela

Statistics

Publications

Citations

216

H-Index

Active since

2014

Affiliations

Arog Pharmaceuticals (United States)(Current)

The University of Texas MD Anderson Cancer Center

Jamil Paradela is an author at Arog Pharmaceuticals (United States) specializing in acute myeloid leukemia therapy, hematology, and hematologic malignancy pharmacotherapy.

Publications per year

2014–2016

Publications

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, Hagop M. Kantarjian, Gautam Borthakur et al. · Blood · 2014 · 115 citations

Medicine, Hematology, Oncology +13

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

Jörge E. Cortes, Hagop M. Kantarjian, Tapan M. Kadia et al. · Journal of Clinical Oncology · 2016 · 101 citations

Medicine, Hematology, Pharmacology +14

1–2 of 2